Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MNMDNASDAQ:PGENOTCMKTS:TBUFFNASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMNMDMind Medicine (MindMed)$7.05-0.6%$6.77$4.70▼$10.44$532.63M2.521.35 million shs1.27 million shsPGENPrecigen$1.45-2.7%$1.43$0.65▼$2.17$428.01M1.851.37 million shs2.11 million shsTBUFFTribute Pharmaceuticals Canada$0.00$0.50▼$1.86$105.76MN/A71,826 shs50,100 shsUPBUpstream Bio$10.88+2.3%$9.54$5.14▼$29.46$585.24MN/A338,281 shs798,298 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMNMDMind Medicine (MindMed)0.00%-1.67%-3.42%+1.88%-4.21%PGENPrecigen0.00%-4.61%+5.84%-20.33%-5.84%TBUFFTribute Pharmaceuticals Canada0.00%0.00%0.00%0.00%0.00%UPBUpstream Bio0.00%-4.23%+18.78%+41.30%+1,087,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMNMDMind Medicine (MindMed)1.4208 of 5 stars3.60.00.00.01.40.80.6PGENPrecigen3.6677 of 5 stars3.51.00.04.71.11.70.6TBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AN/AN/AN/AUPBUpstream Bio1.9115 of 5 stars3.50.00.00.02.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMNMDMind Medicine (MindMed) 3.27Buy$25.50261.70% UpsidePGENPrecigen 3.00Buy$6.00313.79% UpsideTBUFFTribute Pharmaceuticals Canada 0.00N/AN/AN/AUPBUpstream Bio 3.00Buy$56.50419.30% UpsideCurrent Analyst Ratings BreakdownLatest TBUFF, UPB, MNMD, and PGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025PGENPrecigenJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.005/15/2025PGENPrecigenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/13/2025MNMDMind Medicine (MindMed)Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMNMDMind Medicine (MindMed)N/AN/AN/AN/A$3.21 per shareN/APGENPrecigen$3.92M109.19N/AN/A$0.13 per share11.15TBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AN/AUPBUpstream Bio$2.37M246.93N/AN/A$8.77 per share1.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMNMDMind Medicine (MindMed)-$108.68M-$1.29N/AN/AN/AN/A-40.33%-32.13%8/12/2025 (Estimated)PGENPrecigen-$126.24M-$0.56N/AN/AN/A-3,728.87%-279.20%-79.74%8/13/2025 (Estimated)TBUFFTribute Pharmaceuticals CanadaN/AN/A0.00N/AN/AN/AN/AN/AN/AUPBUpstream Bio-$62.81MN/A0.00N/AN/AN/AN/AN/A8/5/2025 (Estimated)Latest TBUFF, UPB, MNMD, and PGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PGENPrecigen-$0.08-$0.07+$0.01-$0.18$0.50 million$1.34 million5/8/2025Q1 2025MNMDMind Medicine (MindMed)-$0.36-$0.35+$0.01-$0.35N/AN/A5/6/2025Q1 2025UPBUpstream Bio-$0.49-$0.51-$0.02-$0.51$0.71 million$0.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ATBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMNMDMind Medicine (MindMed)0.107.277.27PGENPrecigenN/A3.533.53TBUFFTribute Pharmaceuticals CanadaN/AN/AN/AUPBUpstream BioN/A47.4347.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMNMDMind Medicine (MindMed)27.91%PGENPrecigen33.51%TBUFFTribute Pharmaceuticals CanadaN/AUPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipMNMDMind Medicine (MindMed)2.26%PGENPrecigen47.10%TBUFFTribute Pharmaceuticals CanadaN/AUPBUpstream Bio13.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMNMDMind Medicine (MindMed)4075.55 million73.85 millionOptionablePGENPrecigen190295.18 million156.15 millionOptionableTBUFFTribute Pharmaceuticals CanadaN/A113.72 millionN/ANot OptionableUPBUpstream Bio3853.79 million46.50 millionN/ATBUFF, UPB, MNMD, and PGEN HeadlinesRecent News About These CompaniesUpstream Bio (NASDAQ:UPB) Trading 7.8% Higher - Should You Buy?June 20 at 1:45 PM | marketbeat.comUpstream Bio (NASDAQ:UPB) Shares Gap Down - What's Next?June 18, 2025 | marketbeat.comUpstream Bio (NASDAQ:UPB) Trading Down 3.4% - Here's What HappenedJune 16, 2025 | marketbeat.comUpstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody SpaceJune 16, 2025 | tipranks.comUpstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher PotencyJune 16, 2025 | msn.comUpstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI CongressJune 15, 2025 | quiverquant.comTranslational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP ReceptorJune 15, 2025 | globenewswire.comUpstream Bio (NASDAQ:UPB) Raised to Hold at Wall Street ZenJune 7, 2025 | marketbeat.comUpstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025June 5, 2025 | quiverquant.comUpstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025June 5, 2025 | globenewswire.comUpstream Bio (NASDAQ:UPB) Trading Down 3.4% - Should You Sell?June 4, 2025 | marketbeat.comUpstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 4, 2025 | globenewswire.comUpstream Bio (NASDAQ:UPB) Trading 10.2% Higher - Here's What HappenedJune 3, 2025 | marketbeat.com1,583,154 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Purchased by Wellington Management Group LLPJune 1, 2025 | marketbeat.comJane Street Group LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB)May 27, 2025 | marketbeat.comNorthern Trust Corp Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB)May 27, 2025 | marketbeat.comWoodline Partners LP Buys New Stake in Upstream Bio, Inc. (NASDAQ:UPB)May 25, 2025 | marketbeat.comUpstream Bio names new chief technology officerMay 21, 2025 | investing.comUpstream Bio Appoints Stacy Price As CTOMay 21, 2025 | nasdaq.comUpstream Bio, Inc. Appoints Stacy Price as Chief Technology Officer to Lead Expansion of Technical OperationsMay 21, 2025 | nasdaq.comUpstream Bio Appoints Stacy Price as Chief Technology OfficerMay 20, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTBUFF, UPB, MNMD, and PGEN Company DescriptionsMind Medicine (MindMed) NASDAQ:MNMD$7.05 -0.04 (-0.56%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$7.04 -0.01 (-0.14%) As of 06/20/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.Precigen NASDAQ:PGEN$1.45 -0.04 (-2.68%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.45 0.00 (0.00%) As of 06/20/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Tribute Pharmaceuticals Canada OTCMKTS:TBUFFTribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial.Upstream Bio NASDAQ:UPB$10.88 +0.24 (+2.26%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$10.91 +0.03 (+0.28%) As of 06/20/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
